stock-detail (GTXI)

Oncology Corporate Profile

Company Description

This company does not have any commercial products

This company does not have any pipeline products

Recent News Headlines

Loss of SMAD4 Gene in Certain Colorectal Cancers is Associated With Poor Prognosis

11/6/2015 11:03 am

(AACR) Nov 6, 2015 - Among colorectal cancers, loss of the gene SMAD4 was significantly more common in cancers arising in the hindgut (the left side of the colon to the rectum) than in cancers arising in the midgut (the right side of the colon) and patients with hindgut-derived tumors with SMAD4 loss had worse recurrence-free survival compared with those with hindgut-derived tumors that retained SMAD4.

Pediatric Low-grade Gliomas With CRAF Fusions May Require Differential and Combinatorial Targeted Therapies

11/6/2015 11:03 am

(AACR) Nov 6, 2015 - Unlike pediatric low-grade gliomas (PLGG) that are driven by BRAF fusion proteins, PLGGs that are driven by other forms of RAF fusion proteins, called CRAF fusion proteins, may not respond to single-agent therapy with FDA-approved and investigational RAF inhibitors, suggesting the importance of molecularly stratifying PLGG patients in order to identify appropriate therapies.

Takeda to Present Data from Ixazomib's Phase 3 Study in Relapsed/Refractory Multiple Myeloma at Upcoming American Society of Hematology Annual Meeting

11/6/2015 11:03 am

(Takeda) Nov 5, 2015 - Takeda Pharmaceutical Company Limited today announced that it will present Phase 3 data from the TOURMALINE-MM1 ixazomib clinical trial at the 57th American Society of Hematology (ASH) Annual Meeting to be held in Orlando, Florida from December 5 to 8, 2015.

Seattle Genetics Announces More Than 20 Presentations at ASH 2015 Highlighting Progress with Broad ADCETRIS® (Brentuximab Vedotin) Development Plan and Multiple Antibody-Drug Conjugate (ADC) Pipeline Programs

11/6/2015 11:03 am

(Yahoo! Finance) Nov 6, 2015 - Seattle Genetics, Inc. today announced that a record number of abstracts were accepted for presentation at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in Orlando, Florida, December 5-8, 2015.

Viralytics and Merck & Co., Inc., Kenilworth, New Jersey, U.S.A. to Collaborate on Combination Clinical Trial of CAVATAK™ and KEYTRUDA® in Lung and Bladder Cancer

11/6/2015 11:03 am

(MarketWatch) Nov 6, 2015 - Viralytics Limited announced today that it has entered into a clinical trial collaboration agreement through subsidiaries of Merck & Co., Inc., Kenilworth, New Jersey, U.S.A. (known as MSD outside the United States and Canada) to evaluate the combination of Viralytics' investigational cancer immunotherapy CAVATAK™, with MSD's KEYTRUDA®, an anti-PD-1 (programmed death receptor-1) therapy.

Gene Editing Credited With Eliminating an Infant's Aggressive Cancer in London

11/6/2015 11:02 am

(Wall Street Journal) Nov 5, 2015 - A novel gene-editing technique has been used to eliminate an infant's aggressive cancer, a small but significant step in the quest to treat deadly diseases by altering the human genome.

The Hottest New Cancer Drugs Depend on Gut Microbes

11/6/2015 11:02 am

(The Atlantic) Nov 5, 2015 - Immunotherapy doesn’t work for everyone, and a series of new studies might explain why.

Why The FDA Rejected A Drug That Cures Lung Cancer -- And What We Can Do To Fix It

11/6/2015 11:02 am

(Forbes) Nov 6, 2015 - Ed Silverman, writing in the Boston Globe October 19th, pointed to lung cancer drug Iressa as a "cautionary tale" against using "surrogate endpoints" – signs that point to, but don't guarantee, a given clinical outcome – for FDA drug approvals.

First Precision Medicine Trial in Cancer Prevention Identifies Molecular-Based Chemoprevention Strategy

11/6/2015 11:02 am

(MD Anderson) Nov 5, 2015 - A team of scientists, led by researchers at The University of Texas MD Anderson Cancer Center and University of California, San Diego Moores Cancer Center, report that a genetic biomarker called loss of heterozygosity or LOH is able to predict which patients with premalignant mouth lesions are at highest risk of developing oral cancer.

TCGA Findings on Papillary Renal Cell Carcinoma and Prostate Cancer

11/6/2015 11:02 am

(NCI News Note) Nov 5, 2015 - Two findings from The Cancer Genome Atlas (TCGA) Research Network were recently published on papillary renal cell carcinoma and prostate cancer.

The Lancet: Adding Ultrasound to Breast Screening Results in Higher Rate of Detection for Women in Japan

11/6/2015 11:02 am

(Science Codex) Nov 5, 2015 - Adding ultrasound to standard mammography tests in breast screening could result in improved rates of detection for breast cancer in women in Japan, according to a new study, published in The Lancet.

Gut Bacteria Can Dramatically Amplify Cancer Immunotherapy

11/6/2015 07:00 am

(University of Chicago Medicine) Nov 5, 2015 - By introducing a particular strain of bacteria into the digestive tracts of mice with melanoma, researchers at the University of Chicago were able to boost the ability of the animal's immune systems to attack tumor cells.

A Cell Therapy Untested in Humans Saves a Baby With Cancer

11/6/2015 07:00 am

(New York Times) Nov 5, 2015 - A baby girl who was close to dying from cancer has been rescued by a cell therapy envisioned as a “one size fits all” treatment that had never been tested in people, doctors reported on Thursday.

Key Data For Amgen Medicines In Relapsed Multiple Myeloma And Acute Lymphoblastic Leukemia To Be Presented At ASH 2015

11/5/2015 12:03 pm

(Amgen) Nov 5, 2015 - Amgen today announced that a number of important abstracts from the Company's oncology portfolio, including Kyprolis® (carfilzomib) for Injection, BLINCYTO® (blinatumomab), Nplate® (romiplostim) and Neulasta® (pegfilgrastim), are scheduled for presentation at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition, Dec. 5–8, 2015, in Orlando, Fla.

New Gene Linked to Lung Cancer Spread and Tumor Formation

11/5/2015 12:03 pm

(Northwestern University) Nov 4, 2015 - Worldwide, lung cancer causes more deaths than any other cancer. Most frequently, mortality is the result of metastasis -- when lung cancer spreads to other parts of the body, such as the brain, bones or liver.

Steiner Resigns From GTx

4/4/2014 12:01 pm

(Memphis Business Journal) Apr 4, 2014 - Mitch Steiner, CEO and co-founder of GTx Inc., has resigned, effective yesterday.

Novel Findings from Clinical Studies Examining the Effects of Capesaris® (GTx-758) for the Treatment of Advanced Prostate Cancer to be Presented at 2013 American Society of Clinical Oncology Genitourinary Cancer Symposium

2/13/2013 12:01 pm

(Miami Herald) Feb 13, 2013 - GTx, Inc. announced today that new data from two Phase II studies on the effects of Capesaris® (GTx-758), a selective estrogen receptor alpha agonist, for the treatment of advanced prostate cancer, will be detailed in presentations at the ASCO Genitourinary Cancer Symposium in Orlando, Florida.

Comparable Patterns of Failure between SBRT, Lobectomy or Pneumonectomy for Stage I Non-small Cell Lung Cancer

1/15/2013 12:00 pm

(IASLC) Jan 15, 2013 - For patients with medically operable clinical stage I non–small-cell lung cancer (NSCLC), lobectomy or pneumonectomy is the standard approach.

GTx Announces FDA's Grant of Fast Track Designation to Enobosarm For the Prevention and Treatment of Muscle Wasting in Patients with Non-Small Cell Lung Cancer

1/8/2013 12:01 pm

(4-traders) Jan 8, 2013 - GTx, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated enobosarm (GTx-024) for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer as a Fast Track development program.

GTx Attains Enrollment Goal for its Enobosarm POWER 1 and POWER 2 Phase III Clinical Studies

12/17/2012 11:03 am

(Yahoo! Finance) Dec 17, 2012 - GTx, Inc. today announced that it has attained its enrollment goal for both of its pivotal Phase III clinical studies of enobosarm to prevent and treat muscle wasting in non-small cell lung cancer patients.

Memphis-based GTx Sells Cancer Drug Fareston for $21.7M

10/1/2012 01:00 pm

(Memphis Commercial Appeal) Oct 1, 2012 - GTx Inc. has sold Fareston, its breast cancer drug, to U.K.-based ProStrakan Group for $21.7 million.

GTx Announces Presentations on the Effect of Enobosarm on Improving Physical Function In Cancer Patients

6/26/2012 11:00 am

[Business Wire] - GTx, Inc. announced today there will be two scientific presentations on the effects of enobosarm, a selective androgen receptor modulator , on improving physic

GTx Announces Presentation on Enobosarm’s Improvement in Physical Function in Cancer Patients with Both Low and Normal Testosterone Levels

6/25/2012 01:00 pm

[Business Wire] - GTx, Inc. announced today that in a Phase IIb clinical study of enobosarm, there was significantly improved physical function after 16 weeks of treatment, compared to placebo, in both hypogonadal and eugonadal subjects.